Decoding Women’s Cancer: How Biomarkers

Are Redefining Cancer Care

Cancer remains a leading cause of mortality worldwide, with women’s cancers, such as breast, endometrial, ovarian and cervical cancers, posing significant health challenges. Biomarkers, defined as measurable biological indicators of normal or pathogenic processes, are transforming the landscape of oncology by enabling precise diagnosis, prognosis, and treatment selection (National Cancer Institute, 2021). In women’s oncology, the discovery of new biomarkers is enhancing risk stratification—categorizing patients based on their likelihood of disease progression or recurrence—and guiding personalized treatment choices. This article explores recent advancements in biomarker discovery across breast, endometrial, ovarian, and cervical cancers, highlighting their impact on patient care and the promise of precision medicine.

Biomarkers are biological signals ranging from DNA mutations in blood to proteins in tumor tissue that provide clues about cancer risk, progression, and how well a treatment works. In women's oncology, identifying the right biomarker can mean the difference between generic care and highly personalized therapy.

These are the typical biomarkers found in our blood and excretions (Khan et al., 2022).

Precision Through Blood: The Rise of Liquid Biopsies

(Lone et al., 2022)

Liquid biopsies analyze circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), tumor proteins, and exosomes in blood, offering a noninvasive window into the genetic makeup of cancer. For instance, England’s NHS now uses ctDNA testing for breast and lung patients, enabling earlier detection of resistance mutations and faster access to targeted drugs (Gregory, 2025).

Beyond Genetics: Multi-Omics in Endometrial & Ovarian Cancer

Biomarker discovery isn't just about DNA. In ovarian cancer, multi-omics, which is the combination of genomics, proteomics, and transcriptomics, has helped identify:

• Homologous recombination deficiency (HRD), guiding PARP inhibitors, especially beyond BRCA-mutated tumors (ACCC, 2025).
• MSI, TMB, and PD-L1 expression, which help determine eligibility for immunotherapy (Sureka & Zaheer, 2025).
• Antigens like folate receptor-α, targets for antibody-drug conjugates (ADCs) in resistant ovarian cancer (Sureka & Zaheer, 2025).

Similarly, endometrial cancer studies use proteomic and metabolomic profiles from blood or urine to detect early diseases and monitor recurrence (An et al., 2025).

Endometrial cancer metabolic biomarkers research (Njoku et al., 2020)

Why It’s a Game-Changer for Women’s Health

1. Adaptive treatment: With liquid biopsies, doctors can change the therapy course as soon as resistance emerges.
2. Broader applicability: Biomarkers are now guiding care across more cancers from breast and ovarian to uterine and rare gynecologic tumors.
3. Human impact: Less invasive testing, more personalized options, and improved survival are giving women more time and hope with family.

References